EA201991818A1 - Лечение рака - Google Patents

Лечение рака

Info

Publication number
EA201991818A1
EA201991818A1 EA201991818A EA201991818A EA201991818A1 EA 201991818 A1 EA201991818 A1 EA 201991818A1 EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A EA201991818 A EA 201991818A EA 201991818 A1 EA201991818 A1 EA 201991818A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
erdafitinib
provides
present
treating cancer
Prior art date
Application number
EA201991818A
Other languages
English (en)
Inventor
Ким Стейкенс
Хуан Хосе Перес Руиксо
Питер Мари З. Де Порре
Энджели Нарайан Эведхэни
Иоанн Лорьо
Арлен О. Сифкер-Радтке
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201991818A1 publication Critical patent/EA201991818A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

В настоящем изобретении предусмотрен способ лечения рака с помощью эрдафитиниба.
EA201991818A 2017-12-20 2018-02-02 Лечение рака EA201991818A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
EA201991818A1 true EA201991818A1 (ru) 2020-02-05

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991818A EA201991818A1 (ru) 2017-12-20 2018-02-02 Лечение рака

Country Status (5)

Country Link
EA (1) EA201991818A1 (ru)
MA (1) MA47408B1 (ru)
PT (1) PT3576740T (ru)
TW (1) TWI798199B (ru)
WO (1) WO2018141921A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53655A (fr) * 2018-09-21 2021-12-29 Janssen Pharmaceutica Nv Traitement du cholangiocarcinome
EP3898615A1 (en) * 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
AU2020223467A1 (en) * 2019-02-12 2021-08-05 Janssen Pharmaceutica Nv Cancer treatment
CA3133348A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
MX2021011943A (es) * 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
CN114207151A (zh) * 2019-05-31 2022-03-18 Qed医药股份有限公司 治疗泌尿***癌症的方法
US20230011935A1 (en) * 2019-12-09 2023-01-12 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
IL295514A (en) * 2020-02-12 2022-10-01 Janssen Pharmaceutica Nv fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle-invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Also Published As

Publication number Publication date
MA47408A (fr) 2019-12-11
WO2018141921A1 (en) 2018-08-09
PT3576740T (pt) 2023-08-18
MA47408B1 (fr) 2023-08-31
TW201839399A (zh) 2018-11-01
TWI798199B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
EA201991818A1 (ru) Лечение рака
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
PH12017501999A1 (en) K-ras modulators
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
EA202091881A1 (ru) Соединения для лечения боли
MX2020006297A (es) Variantes de cd19.
KR102377742B1 (ko) 암치료약
EA202191086A1 (ru) Комбинированная терапия меланомы
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
BR112019004276A2 (pt) métodos para o tratamento de câncer ovariano
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
EA202192163A1 (ru) Лечение рака
EA202190833A1 (ru) Bt1718 для применения при лечении рака
CL2019000698S1 (es) Calefactor de inducción